ATE355289T1 - 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden - Google Patents

1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden

Info

Publication number
ATE355289T1
ATE355289T1 AT03734366T AT03734366T ATE355289T1 AT E355289 T1 ATE355289 T1 AT E355289T1 AT 03734366 T AT03734366 T AT 03734366T AT 03734366 T AT03734366 T AT 03734366T AT E355289 T1 ATE355289 T1 AT E355289T1
Authority
AT
Austria
Prior art keywords
sulfonylazaindole
hydroxytryptamine
aminoalkyl
ligands
Prior art date
Application number
AT03734366T
Other languages
English (en)
Inventor
Ronald Charles Bernotas
Steven Edward Lenicek
Schuyler A Antane
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE355289T1 publication Critical patent/ATE355289T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT03734366T 2002-06-04 2003-06-03 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden ATE355289T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38550202P 2002-06-04 2002-06-04

Publications (1)

Publication Number Publication Date
ATE355289T1 true ATE355289T1 (de) 2006-03-15

Family

ID=29712180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03734366T ATE355289T1 (de) 2002-06-04 2003-06-03 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden

Country Status (25)

Country Link
US (3) US6825212B2 (de)
EP (1) EP1509522B1 (de)
JP (1) JP2005532349A (de)
KR (1) KR20050013565A (de)
CN (1) CN1315827C (de)
AR (1) AR040047A1 (de)
AT (1) ATE355289T1 (de)
AU (1) AU2003239954A1 (de)
BR (1) BR0311591A (de)
CA (1) CA2486191A1 (de)
DE (1) DE60312155T2 (de)
DK (1) DK1509522T3 (de)
EC (1) ECSP045474A (de)
ES (1) ES2282637T3 (de)
IL (1) IL165487A0 (de)
MX (1) MXPA04011331A (de)
NO (1) NO20044763L (de)
NZ (1) NZ536959A (de)
PT (1) PT1509522E (de)
RU (1) RU2315048C2 (de)
SI (1) SI1509522T1 (de)
TW (1) TW200408638A (de)
UA (1) UA78999C2 (de)
WO (1) WO2003101990A1 (de)
ZA (1) ZA200500022B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US7592340B2 (en) 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP2008508358A (ja) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
WO2006065710A1 (en) * 2004-12-14 2006-06-22 Wyeth Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
BRPI0611948A2 (pt) * 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
UA95244C2 (ru) 2005-06-22 2011-07-25 Плексикон, Инк. Соединения и способ модулирования активности киназ, и показания для их применения
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007067537A1 (en) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
UA95940C2 (uk) 2006-01-17 2011-09-26 Вертекс Фармасьютикалс Інкорпорейтед Азаіндоли як інгібітори кіназ януса
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
EP2162132A4 (de) * 2007-05-21 2013-01-16 Sgx Pharmaceuticals Inc Heterozyklische kinasemodulatoren
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
AU2011248175A1 (en) * 2010-05-06 2012-10-25 Merck Sharp & Dohme Corp. Aza-Indole derivatives useful as modulators of FAAH
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
EP3294735B8 (de) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Hemmer der influenzavirenreplikation
EP3294717B1 (de) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Verfahren zur herstellung von inhibitoren der influenzavirenreplikation
EP3519816A4 (de) 2016-09-29 2020-05-06 The Regents of the University of California Verbindungen zur erhöhung der neuronalen plastizität
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
EP4165049A4 (de) * 2020-06-10 2024-09-11 Delix Therapeutics, Inc. Isotryptamin-psycoplastiogene und verwendungen davon
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US625923A (en) * 1899-05-30 Magneto-bell striker
US4654360A (en) 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
FR2642755B1 (de) * 1989-02-07 1993-11-05 Sanofi
US5132319A (en) 1991-03-28 1992-07-21 Merck Frosst Canada, Inc. 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
GB9503377D0 (en) 1995-02-21 1995-04-12 Merck Sharp & Dohme Therapeutic agents
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PL198983B1 (pl) 1998-04-28 2008-08-29 Elbion Ag Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania
EP1204662B1 (de) * 1999-08-12 2004-06-02 NPS Allelix Corp. Azaidole mit serotonin rezeptor affinität
CA2407677A1 (en) 2000-04-28 2002-10-28 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
BR0210929A (pt) 2001-06-07 2004-06-08 Hoffmann La Roche Derivados de indol com afinidade para o receptor 5-ht6
EP1414442A1 (de) * 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl-indole, -benzofurane und -benzothiophene mit 5-ht6-rezeptor-affinität für die behandlung von erkrankungen des zentralen nervensystems
WO2003080608A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6

Also Published As

Publication number Publication date
BR0311591A (pt) 2005-03-01
US6825212B2 (en) 2004-11-30
NZ536959A (en) 2007-04-27
TW200408638A (en) 2004-06-01
US7585873B2 (en) 2009-09-08
US20060148831A1 (en) 2006-07-06
DE60312155T2 (de) 2007-11-22
CN1659166A (zh) 2005-08-24
PT1509522E (pt) 2007-05-31
ECSP045474A (es) 2005-01-28
CN1315827C (zh) 2007-05-16
US7074792B2 (en) 2006-07-11
KR20050013565A (ko) 2005-02-04
AU2003239954A1 (en) 2003-12-19
MXPA04011331A (es) 2005-02-14
HK1071371A1 (en) 2005-07-15
EP1509522A1 (de) 2005-03-02
IL165487A0 (en) 2006-01-15
SI1509522T1 (sl) 2007-06-30
ES2282637T3 (es) 2007-10-16
RU2004139068A (ru) 2005-06-27
US20050085481A1 (en) 2005-04-21
UA78999C2 (en) 2007-05-10
AR040047A1 (es) 2005-03-09
EP1509522B1 (de) 2007-02-28
WO2003101990A1 (en) 2003-12-11
JP2005532349A (ja) 2005-10-27
DK1509522T3 (da) 2007-04-16
DE60312155D1 (de) 2007-04-12
ZA200500022B (en) 2006-06-28
RU2315048C2 (ru) 2008-01-20
US20030236278A1 (en) 2003-12-25
CA2486191A1 (en) 2003-12-11
NO20044763L (no) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE355289T1 (de) 1-(aminoalkyl)-3-sulfonylazaindole als 5- hydroxytryptamin-6 liganden
DE60310552D1 (de) 1-(aminoalkyl)-3-sulfonylindol und -indazol derivative als 5-hydroxytryptamin-6 liganden
ATE396191T1 (de) Azaindolylalkylaminderivate als 5- hydroxytryptamin-6-liganden
ATE312078T1 (de) 1-aryl-oder 1-alkylsulfonylbenzazol derivate als 5-hydroxytryptamin-6 liganden
DE60336811D1 (de) Neue benzimidazolderivate
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
NO20052514D0 (no) Polysilazanholdig beleggingsopplosning
IS7730A (is) Ný fenanþrídín
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
ZA200500435B (en) 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands
ATE335477T1 (de) Indolylalkylamin-derivate als 5-hydroxytryptamin- 6 liganden
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE60308670D1 (de) Substituierte indole als alpha-1 agonisten
ATE354631T1 (de) Nuancierungsmittel
ATE327232T1 (de) Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
ATE421506T1 (de) Neue benzimidazolderivate
ZA200506416B (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
DK1566378T3 (da) Isoindolinderivat
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren
EP1486553A4 (de) Neues entparaffinierungshilfsmittel
FI20031408A0 (fi) Säilöntälaitteisto
FI20021545L (fi) Lignaalikomplekseja
PL378439A1 (pl) Środki depigmentujące

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1509522

Country of ref document: EP

REN Ceased due to non-payment of the annual fee